Your browser doesn't support javascript.
loading
COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report.
Ramos-Ruperto, Luis; Busca-Arenzana, Carmen; Valdivieso, Juan; López-Granados, Eduardo; Robles-Marhuenda, Ángel.
Afiliación
  • Ramos-Ruperto L; Internal Medicine Department, Hospital La Paz, Madrid, Spain.
  • Busca-Arenzana C; Internal Medicine Department, Hospital La Paz, Madrid, Spain.
  • Valdivieso J; Immunology Department, Hospital La Paz, Madrid, Spain.
  • López-Granados E; Immunology Department, Hospital La Paz, Madrid, Spain.
  • Robles-Marhuenda Á; Internal Medicine Department, Hospital La Paz, Madrid, Spain.
SN Compr Clin Med ; 3(6): 1412-1415, 2021.
Article en En | MEDLINE | ID: mdl-33824942
ABSTRACT
Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis. Although it is a rare complication, it must be suspected in order to start specific treatment. In this context, intravenous immunoglobulins could be a therapeutic option.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: SN Compr Clin Med Año: 2021 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: SN Compr Clin Med Año: 2021 Tipo del documento: Article País de afiliación: España